ReviewNature reviews. Rheumatology2010
Systemic amyloidosis: a challenge for the rheumatologist.
Review in Nature reviews. Rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04612582 (A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）
Who cites it
26 citing papers in PubMed, 86 citations in OpenAlex.
- Amyloid Myopathy: A Cunning Masquerader.Cureus · 2023Article
- Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease.Biomedicines · 2022Review
- Primary nasopharyngeal amyloidosis with nasal polyposis: Case report of a diagnostic challenge.International journal of surgery case reports · 2022Article
- [A case of lambda-light chain type primary amyloidosis with abdominal pain as the initial manifestation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Kidney disease in a child with familial Mediterranean fever: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- High-resolution ultrasound of peripheral neuropathies in rheumatological patients: An overview of clinical applications and imaging findings.Frontiers in medicine · 2022Review
- Carpal tunnel syndrome in patients with arteriovenous fistula for haemodialysis: A narrative review of the current literature.The journal of vascular access · 2021Review
- Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment.Molecules (Basel, Switzerland) · 2021Review
- Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.BMC nephrology · 2021Article
- Multifocal head and neck amyloidosis as a diagnostic clue of systemic lupus erythematosus (SLE): A case report.Medicine · 2019Article
- Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis.Journal of neuromuscular diseases · 2019Review
- Accelerated pre-senile systemic amyloidosis in PACAP knockout mice - a protective role of PACAP in age-related degenerative processes.The Journal of pathology · 2018Article
- Isolated AA Amyloidosis of the Radial Nerve.Hand (New York, N.Y.) · 2017Article
- Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.Arquivos brasileiros de cardiologia · 2017Review
- Review
- The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China.Kidney diseases (Basel, Switzerland) · 2016Review
- Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.BMJ case reports · 2016Article
- A young patient with recurrent respiratory tract infection and anasarca.BMJ case reports · 2013Article
- A Rare Cause of Diffuse Parenchymal Lung Disease together with Granulomatous Reaction: Pulmonary Amyloidosis.Case reports in pulmonology · 2013Article
- Renal transplantation in patients with familial Mediterranean fever.Clinical rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis comprises a group of diseases characterized by the extracellular deposition of insoluble fibrillar proteins. This mechanism generates different clinical syndromes depending on the site and extent of organ involvement. Amyloidosis is classified into categories of systemic and localized disease. Systemic amyloidosis is further subdivided into a hereditary familial form (for example, ATTR amyloidosis), a reactive form (AA amyloidosis), dialysis-related (Abeta(2)M) amyloidosis and immunoglobulin light chain (AL) amyloidosis. Treatment can be symptomatic, directed at the affected organ, or can be directed at reducing the production of the abnormal proteins with different strategies. Despite advances in treatment, the prognosis is still poor and depends on the underlying disease as well as the type and degree of dysfunction in involved organs. Early diagnosis is essential because patients with advanced disease are generally unable to undergo intensive therapy. Patients with systemic amyloidosis often present to a rheumatologist not only because the disease can include musculoskeletal and articular symptoms but also because it can be associated with chronic rheumatic diseases. This Review discusses the clinical features of amyloidosis and its rheumatic manifestations. The various types of amyloidosis, as well their prognosis and treatment, are also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.